A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma

BACKGROUND: Small cell lung cancer (SCLC) is a common lung cancer which presents with extensive stage disease at time of diagnosis in two-thirds of patients. For treatment of advanced disease, traditional platinum doublet chemotherapy induces response rates up to 80% but with few durable responses....

Descripción completa

Detalles Bibliográficos
Autores principales: Lycan, Thomas W., Pardee, Timothy S., Petty, William J., Bonomi, Marcelo, Alistar, Angela, Lamar, Zanetta S., Isom, Scott, Chan, Michael D., Miller, Antonius A., Ruiz, Jimmy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061374/
https://www.ncbi.nlm.nih.gov/pubmed/27732654
http://dx.doi.org/10.1371/journal.pone.0164244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061374/
https://www.ncbi.nlm.nih.gov/pubmed/27732654
http://dx.doi.org/10.1371/journal.pone.0164244

Ejemplares similares